ImpediMed

ImpediMed Tax Expense

The Income Tax Expense of ImpediMed (IPD.AX) as of Nov 12, 2026 is -1.18 M AUD. In the previous year, Income Tax Expense was 26,000.00 AUD — a change of -4,650.00% (lower).

Tax Expense

-1.18 MAUD

YoY

-4,650.00%

Last updated:

Income Tax Expense of ImpediMed is 2026 -1.18 M AUD. Income Tax Expense of ImpediMed was 2025 26,000.00 AUD. It decreases by -4,650.00% lower compared to the previous year.

The ImpediMed Tax Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tax Expense
Date
Tax Expense
Jan 1, 2019
51,000.00 AUD
Jan 1, 2020
-2.56 M AUD
Jan 1, 2021
-1.75 M AUD
Jan 1, 2022
-1.57 M AUD
Jan 1, 2023
-1.56 M AUD
Jan 1, 2024
-935,000.00 AUD
Jan 1, 2025
26,000.00 AUD
Jan 1, 2026
-1.18 M AUD
The ImpediMed Tax Expense history
YEARTax ExpenseYoY
-1.18 MAUD-4,650.00%
26,000.00AUD-102.78%
-935,000.00AUD-39.87%
-1.56 MAUD-1.14%
-1.57 MAUD-10.06%
-1.75 MAUD-31.63%
-2.56 MAUD-5,115.69%
51,000.00AUD+21.43%
42,000.00AUD+5.00%
40,000.00AUD-101.70%
-2.35 MAUD—
0.00AUD—
0.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Income Tax Expense of ImpediMed is -1.18 M AUD in 2026.

Income Tax Expense of ImpediMed changed from 26,000.00 AUD to -1.18 M AUD, representing a -4,650.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Income Tax Expense ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.

Income Tax Expense's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's ImpediMed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ImpediMed

All Key Metrics — ImpediMed